Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-idiotype anti-CEA antibody molecules and its use as cancer vaccine

An anti-idiotypic and molecular technology, applied in the direction of antibody medical ingredients, medical preparations containing active ingredients, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, etc.

Inactive Publication Date: 2005-07-27
MERCK PATENT GMBH
View PDF30 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However more recent trials suggest that antibody alone may not be effective in patients with large tumors and that a vaccination strategy with this antibody may be more beneficial in patients with minimal residual disease [Maxwell-Armstrong, C.A. et al (2001) Bri. J. Cancer 84:1443-1446]

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-idiotype anti-CEA antibody molecules and its use as cancer vaccine
  • Anti-idiotype anti-CEA antibody molecules and its use as cancer vaccine
  • Anti-idiotype anti-CEA antibody molecules and its use as cancer vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0064] The molecules of the invention are modified antibody molecules that have utility as active components of anti-cancer vaccines. The present invention thus relates to the therapeutic treatment of human diseases. This molecule is derived from an anti-idiotypic antibody called 708. The 708 monoclonal antibody was prepared against the anti-CEA monoclonal antibody NCRC23. The natural 708 antibody can prevent the interaction between NCRC23 and its antigen and both can induce antibody and T cell responses that specifically recognize the antigen, but the natural mouse 708 antibody cannot stimulate lymphocytes from normal donors [Durrant, L.G. et al. (1992) , the source is the same as above]. Many modifications have been made to the natural 708 antibody to improve its ability to act as an anticancer vaccine. Modifications result in compositions as disclosed herein and are embodiments of the invention. All modifications to the native (parental) mouse 708 antibody can be perfor...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides molecules, preferably designed immunoglubulins, suitable for use as an anti-idiotype vaccine to CEA positive tumours. The molecules induce both an MHC class I and MHC class II mediated immune response to the CEA bearing tumour cells for an efficient and sustained host anti-tumour response. The present invention provides modified versions of anti-idiotype anti-CEA antibodies, preferably mouse antibody 708, with improved vaccination properties. The modifications are related to the introduction of sequences tracts deriving from e.g. CEA, CD55 antigen and CEA cancer-specific MHC epitopes into the variable regions of said antibody molecules.

Description

field of invention [0001] The present invention provides molecules, preferably designer immunoglobulins, useful as anti-idiotypic vaccines against CEA (carcinoembryonic antigen) positive tumors. Said molecule can induce MHC class I and MHC class II mediated immune response to CEA tumor-bearing cells, so as to generate effective and durable host anti-tumor response. The present invention provides anti-idiotypic anti-CEA antibodies, preferably modified forms of mouse antibody 708, with improved vaccine properties. This modification involves the introduction of sequence segments from, for example, CEA, CD55 antigen, and CEA cancer-specific MHC epitopes into the variable region of the antibody molecule. Background technique [0002] It has long been desired to provide compositions that stimulate or enhance the interaction of the human immune system with cancer cells to eliminate cancer cells from the body. Unlike vaccination, which provides immunity to infectious agents, harne...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/09A61K38/00A61K39/00A61K39/395A61P35/00C07K16/08C07K16/28C07K16/30C07K16/42C07K16/46C07K19/00
CPCC07K16/4266C07K2317/565C07K16/2896C07K16/3007C07K2318/10A61K39/00A61P35/00A61K39/395C07K16/42C07K16/46
Inventor G·卡特F·J·卡尔
Owner MERCK PATENT GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com